Transcatheter Aortic Valve Implantation (TAVI)





The interactive transcript could not be loaded.



Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 15, 2012

Transcatheter aortic valve replacement (TAVR) is a new and innovative approach to the treatment of severe aortic stenosis (narrowing of the aortic valve opening). Instead of standard open heart surgery, a balloon catheter is placed in the femoral artery (in the groin) and guided into the heart. A compressed heart valve is then placed in the catheter and positioned directed inside the diseased aortic valve. Once in position, the balloon is inflated to secure the valve in place.

Also known as transcatheter aortic valve implantation (TAVI), this procedure is for patients suffering from aortic stenosis who are considered at high risk for surgery due to advanced age or other serious illness.

The transfemoral (above the knee) approach is now approved by the FDA for patients who have severe, symptomatic aortic stenosis and who are ineligible for open heart surgery. It is not approved for patients who are eligible for traditional aortic valve surgery, patients with bicuspid aortic valves or endocarditis, or patients who cannot tolerate anticoagulation/antiplatelet medication therapy.

In clinical trials, TAVR has been shown to significantly improve survival compared to non-surgical therapy. It also significantly improves symptoms, quality-of-life and reduces repeat hospitalizations compared to medical therapy.

For more information about TAVR at Maimonides Medical Center, please visit:

  • Category

  • License

    • Standard YouTube License


When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...